Peirce, Susan K <br/><br/>
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Aug 2011 
 - 325-35 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-010-1486-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--antagonists & inhibitors<br/>Apoptosis--drug effects<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Chromones--antagonists & inhibitors<br/>Enzyme Inhibitors--pharmacology<br/>Female<br/>Humans<br/>Inhibitor of Apoptosis Proteins--metabolism<br/>Mice<br/>Mice, Nude<br/>Neuroblastoma--drug therapy<br/>Oligopeptides--antagonists & inhibitors<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Phosphorylation--drug effects<br/>Prodrugs--pharmacology<br/>Protein Processing, Post-Translational--drug effects<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Proto-Oncogene Proteins c-mdm2--metabolism<br/>Random Allocation<br/>Signal Transduction--drug effects<br/>Survivin<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays